| Optical coherence tomography findings during pegaptanib therapy for neovascular age-related macular degeneration. | |
| | |
MedLine Citation:
|
PMID: 17621181 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: To evaluate macular thickness measured by optical coherence tomography (OCT) during pegaptanib therapy for neovascular age-related macular degeneration (AMD). METHODS: For this prospective, nonrandomized, observational case series, 41 eyes from 41 patients with neovascular AMD received intravitreous pegaptanib (1 mg) injections repeated every 6 weeks. The primary outcome measure was central foveal thickness measured by OCT. Secondary outcomes were fluorescein angiographic leakage and visual acuity. RESULTS: Mean thickness of the central area on OCT decreased from 340 +/- 24 microm to 299 +/- 14 microm after 12 weeks of pegaptanib injections. This represents a reduction in thickening of 32%. Fluorescein angiograms with definite leakage decreased from 100% to 81%, and mean visual acuity decreased from 20/116 to 20/120. CONCLUSIONS: Intravitreal injections of pegaptanib at 6-week intervals result in a moderate reduction of central foveal thickness in eyes with subfoveal neovascular AMD. This presents a modest effect relative to that reported with other anti-angiogenic agents. |
| | |
Authors:
|
Geoffrey G Emerson; Christina J Flaxel; Andreas K Lauer; J Timothy Stout; M Vaughn Emerson; Susan Nolte; David J Wilson; Michael L Klein |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Retina (Philadelphia, Pa.) Volume: 27 ISSN: 0275-004X ISO Abbreviation: Retina (Philadelphia, Pa.) Publication Date: 2007 Jul-Aug |
Date Detail:
|
Created Date: 2007-07-10 Completed Date: 2007-08-13 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8309919 Medline TA: Retina Country: United States |
Other Details:
|
Languages: eng Pagination: 724-9 Citation Subset: IM |
Affiliation:
|
Casey Eye Institute, Oregon Health & Science University, Portland, OR, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Aged, 80 and over Angiogenesis Inhibitors / therapeutic use* Aptamers, Nucleotide / therapeutic use* Choroidal Neovascularization / diagnosis, drug therapy* Female Fluorescein Angiography Follow-Up Studies Fovea Centralis Humans Injections Macular Degeneration / complications* Macular Edema / diagnosis*, etiology Male Middle Aged Prospective Studies Tomography, Optical Coherence* Vascular Endothelial Growth Factor A / antagonists & inhibitors Vitreous Body |
| Chemical | |
Reg. No./Substance:
|
0/Angiogenesis Inhibitors; 0/Aptamers, Nucleotide; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 0/pegaptanib |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membran...
Next Document: Melanocytoma (hyperpigmented magnocellular nevus) of the uveal tract: the 34th G. Victor Simpson lec...